SKYHAWK THERAPEUTICS
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.
SKYHAWK THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2016-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.skyhawktx.com
Total Employee:
11+
Status:
Active
Contact:
617.858.0041
Email Addresses:
[email protected]
Total Funding:
181.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Venture Round - Skyhawk Therapeutics
Good Growth Capital
Good Growth Capital investment in Series A - Skyhawk Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Venture Round - Skyhawk Therapeutics
ShangPharma Innovation
ShangPharma Innovation investment in Venture Round - Skyhawk Therapeutics
Agent Capital
Agent Capital investment in Venture Round - Skyhawk Therapeutics
Tim Disney
Tim Disney investment in Venture Round - Skyhawk Therapeutics
GreatPoint Ventures
GreatPoint Ventures investment in Venture Round - Skyhawk Therapeutics
The Duke of Bedford
The Duke of Bedford investment in Venture Round - Skyhawk Therapeutics
Celgene
Celgene investment in Venture Round - Skyhawk Therapeutics
Good Growth Capital
Good Growth Capital investment in Series A - Skyhawk Therapeutics
Official Site Inspections
http://www.skyhawktx.com Semrush global rank: 5.01 M Semrush visits lastest month: 1.67 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Skyhawk Therapeutics"
Skyhawk Therapeutics - Overview, News & Similar companies
View Skyhawk Therapeutics (www.skyhawktx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Skyhawk Therapeutics Company Profile 2024: …
Skyhawk Therapeutics General Information Description. Developer of small molecule drugs designed to offer therapies that correct ribonucleic acid expression. The company's drugs use proprietary technology that assists the …See details»
Working At Skyhawk Therapeutics: Company Overview and …
Mar 14, 2024 skyhawktx.com. Organization Type. Private. CEO. William Haney. Social Media. Skyhawk Therapeutics is focused on discovering, developing and commercializing therapies …See details»
Ipsen and Skyhawk Therapeutics announce RNA targeting research ...
Apr 22, 2024 Email: [email protected]. Ipsen Disclaimers and/or Forward-Looking Statements. The forward-looking statements, objectives and targets contained herein are …See details»
Ipsen and Skyhawk Therapeutics announce RNA targeting research ...
Apr 22, 2024 For more information visit www.skyhawktx.com. Ipsen contacts. Email: [email protected] Amy Wolf | +41 7 95 76 07 23 Jess Smith | + 44 7557 267 634. Skyhawk contacts …See details»
Ipsen and Skyhawk Therapeutics announce RNA targeting research ...
Apr 22, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small …See details»
Skyhawk Therapeutics Expands Leadership Team with Chief
Oct 5, 2020 Skyhawk Therapeutics Expands Leadership Team with Chief Medical Officer and Head of Chemistry, and adds to its Scientific Advisory Board FrançaisSee details»
About SKYHAWK THERAPEUTICS | DxMultiomics
_↗ skyhawktx.com. Feb 28, 2024. Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small _↗ skyhawktx.com. Oct 23, 2023See details»
Skyhawk Therapeutics · GitHub
SkyhawkTx. Product Actions. Automate any workflow Packages. Host and manage packages Security. Find and fix vulnerabilities Codespaces. Instant dev environments ... This organization has no public members. You must be a …See details»
Experienced Business Leader in Biopharmaceutical …
Feb 24, 2020 Dr. Connolly also held executive roles in Celgene's Global Alliances organization, Technical Operations, and Process Chemistry, where he contributed to the successful commercialization of Celgene ...See details»
Skyhawk Therapeutics Has Advanced to the Multiple Ascending …
Feb 28, 2024 Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today announced that the Phase 1 multiple …See details»
Skyhawk Therapeutics Announces Positive Topline Results from …
Jul 10, 2024 Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose tested in the multiple …See details»
Skyhawk Therapeutics Presents Compelling Preclinical Data at the ...
BOSTON, Oct. 24, 2024 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate …See details»
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY …
BOSTON, Oct. 24, 2024 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate …See details»
Recommended Stories - Yahoo Finance
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced the company …See details»
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY …
BOSTON, MA, USA I October 24, 2024 I Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate …See details»
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY …
Oct 24, 2024 Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced …See details»
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY …
BOSTON, Oct. 24, 2024 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate …See details»
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY …
Oct 24, 2024 SKY-1214, an IND-ready first-in-class FANCL/FANCI RNA splicing modulator, demonstrates tumor growth inhibition and regression to undetectable levels in NHL and …See details»